NIH stem cell news - or is it?

Written byAlison McCook

| 1 min read

An interesting news release from the NIH landed in my inbox Tuesday (September 18). The headline said the agency "Announces Plan to Implement President's linkurl:Stem Cell;http://www.the-scientist.com/article/display/36654/ Executive Order." I know, I know -- the linkurl:executive order;http://www.the-scientist.com/news/display/53059/ came six years ago. But apparently, now the agency is taking new steps -- for instance, asking for grant applications to study non-embryonic sources of pluripotent cells, and creating two supplemental programs to augment already in-progress stem cell research. The plan also calls for "aggressively pursuing an assessment of the potential of alternative sources of pluripotent stem cell lines, " such as reprogramming somatic cells. "While these methods have been proposed, questions remain as to their feasibility. To address this issue, the NIH will undertake a comprehensive research portfolio review to determine what research NIH is currently supporting in this area and convene a state-of-the-science workshop to identify the key questions," the release notes. "Some of the alternative methods may raise questions under applicable law. In such cases, NIH must carefully consider whether it may fund such research. " That's an interesting comment. I wonder what it will mean. No one answered my phone call to the press contact listed on the release when I called this afternoon. The agency also plans to rename its Human Embryonic Stem Cell Registry the "Human Pluripotent Stem Cell Registry," and will consider adding new linkurl:human pluripotent;http://www.the-scientist.com/news/display/43099/ stem cell lines.

NIH stem cell news - or is it?

The Scientist ARCHIVES

Become a Member of

Meet the Author

Alison McCook

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies